scispace - formally typeset
M

Madhuri Dasari

Researcher at Georgia Institute of Technology

Publications -  11
Citations -  811

Madhuri Dasari is an academic researcher from Georgia Institute of Technology. The author has contributed to research in topics: Hydrogen peroxide & Prodrug. The author has an hindex of 7, co-authored 9 publications receiving 733 citations. Previous affiliations of Madhuri Dasari include Parker H. Petit Institute for Bioengineering & Bioscience & The Wallace H. Coulter Department of Biomedical Engineering.

Papers
More filters
Journal ArticleDOI

In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles

TL;DR: It is demonstrated that nanoparticles formulated from peroxalate esters and fluorescent dyes can image hydrogen peroxide in vivo with high specificity and sensitivity and deep-tissue-imaging capability.
Journal ArticleDOI

Photocrosslinkable chitosan based hydrogels for neural tissue engineering

TL;DR: The development of a novel chitosan based photocrosslinkable hydrogel system with tunable mechanical properties and degradation rates is reported and contributes to an increasing repertoire of hydrogels designed for neural tissue engineering.
Journal ArticleDOI

Detection of hydrogen peroxide with chemiluminescent micelles

TL;DR: The peroxalate micelles are presented, which detect hydrogen peroxide through chemiluminescence, and have the physical/chemical properties needed for in vivo imaging applications, and are anticipated to have numerous applications, given their high sensitivity, small size, and biocompatible PEG corona.
Journal ArticleDOI

Hoechst-IR: An Imaging Agent That Detects Necrotic Tissue in Vivo by Binding Extracellular DNA

TL;DR: Hoechst-IR detects necrosis by binding extracellular DNA released from necrotic cells and was able to image necrosis generated from a myocardial infarction and lipopolysaccharide/d-galactosamine (LPS-GalN) induced sepsis.
Journal ArticleDOI

H-gemcitabine: a new gemcitabine prodrug for treating cancer.

TL;DR: It is demonstrated here that H-gem citabine has a wider therapeutic window than free gemcitabine, and still has high tumor efficacy because of its ability to target gemcitABine to E-DNA in tumors.